So far, CD4+ T cell-mediated killing of either MHC Class II-matched or autologous tumor cells has been demonstrated in melanoma, bladder cancer and glioblastoma (12, 146, 191, 195, 196). This evidence concerns the gene CD4 and urinary bladder carcinoma.